Aghahoseini Fariba, Alihemmati Alireza, Hosseini Leila, Badalzadeh Reza
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
J Diabetes Metab Disord. 2020 Jun 4;19(2):701-707. doi: 10.1007/s40200-020-00548-7. eCollection 2020 Dec.
Vildagliptin has been shown to prevent microvascular complications during diabetes. The aim of this research was to evaluate the antioxidant effects of vildagliptin in diabetic nephropathy.
The diabetes was induced in the animals by high-fat diet and intraperitoneal injection of 35 mg/kg streptozotocin. After diagnosis of diabetes, the vildagliptin (6 mg/kg/day) was orally administered for one month. The biochemical parameters of blood urea nitrogen, creatinine, insulin, and serum albumin were measured. The levels of stress oxidative markers were detected using spectrophotometry.
Treatment with vildagliptin significantly diminished blood glucose, oxidative stress, and reduced creatinine as well as increased insulin secretion. In addition, the vildagliptin improved renal glomerular and tubule interstitial damages and reduced vascular lesions.
The treatment with vildagliptin can be useful in controlling the renal complications of type 2 diabetes mellitus through inhibiting lipid peroxidation and increasing the antioxidant enzymes.
维格列汀已被证明可预防糖尿病期间的微血管并发症。本研究的目的是评估维格列汀在糖尿病肾病中的抗氧化作用。
通过高脂饮食和腹腔注射35mg/kg链脲佐菌素诱导动物患糖尿病。糖尿病诊断后，口服维格列汀（6mg/kg/天）1个月。测量血尿素氮、肌酐、胰岛素和血清白蛋白的生化参数。使用分光光度法检测应激氧化标志物的水平。
维格列汀治疗可显著降低血糖、氧化应激，降低肌酐水平并增加胰岛素分泌。此外，维格列汀改善了肾小球和肾小管间质损伤，减少了血管病变。
维格列汀治疗可通过抑制脂质过氧化和增加抗氧化酶来控制2型糖尿病的肾脏并发症。
